Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 1.16
ILMN's Cash to Debt is ranked lower than
51% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.21 vs. ILMN: 1.16 )
Ranked among companies with meaningful Cash to Debt only.
ILMN' s 10-Year Cash to Debt Range
Min: 0.69  Med: 2.31 Max: No Debt
Current: 1.16
Equity to Asset 0.48
ILMN's Equity to Asset is ranked lower than
68% of the 181 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.60 vs. ILMN: 0.48 )
Ranked among companies with meaningful Equity to Asset only.
ILMN' s 10-Year Equity to Asset Range
Min: 0.36  Med: 0.60 Max: 0.94
Current: 0.48
0.36
0.94
Interest Coverage 12.33
ILMN's Interest Coverage is ranked lower than
68% of the 111 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 53.79 vs. ILMN: 12.33 )
Ranked among companies with meaningful Interest Coverage only.
ILMN' s 10-Year Interest Coverage Range
Min: 3.38  Med: 5.73 Max: 9999.99
Current: 12.33
3.38
9999.99
F-Score: 9
Z-Score: 11.12
M-Score: -2.28
WACC vs ROIC
5.10%
35.71%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 31.41
ILMN's Operating margin (%) is ranked higher than
96% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.48 vs. ILMN: 31.41 )
Ranked among companies with meaningful Operating margin (%) only.
ILMN' s 10-Year Operating margin (%) Range
Min: -1775.02  Med: -0.73 Max: 27.65
Current: 31.41
-1775.02
27.65
Net-margin (%) 23.45
ILMN's Net-margin (%) is ranked higher than
95% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.54 vs. ILMN: 23.45 )
Ranked among companies with meaningful Net-margin (%) only.
ILMN' s 10-Year Net-margin (%) Range
Min: -1421.39  Med: -2.72 Max: 21.65
Current: 23.45
-1421.39
21.65
ROE (%) 33.57
ILMN's ROE (%) is ranked higher than
97% of the 182 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.29 vs. ILMN: 33.57 )
Ranked among companies with meaningful ROE (%) only.
ILMN' s 10-Year ROE (%) Range
Min: -84.48  Med: 6.51 Max: 24.99
Current: 33.57
-84.48
24.99
ROA (%) 14.41
ILMN's ROA (%) is ranked higher than
91% of the 193 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.43 vs. ILMN: 14.41 )
Ranked among companies with meaningful ROA (%) only.
ILMN' s 10-Year ROA (%) Range
Min: -43.21  Med: 3.41 Max: 19.92
Current: 14.41
-43.21
19.92
ROC (Joel Greenblatt) (%) 145.11
ILMN's ROC (Joel Greenblatt) (%) is ranked higher than
97% of the 191 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 11.56 vs. ILMN: 145.11 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ILMN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -508.83  Med: 57.08 Max: 129
Current: 145.11
-508.83
129
Revenue Growth (3Y)(%) 18.00
ILMN's Revenue Growth (3Y)(%) is ranked higher than
90% of the 151 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.00 vs. ILMN: 18.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ILMN' s 10-Year Revenue Growth (3Y)(%) Range
Min: -2  Med: 37.00 Max: 160.9
Current: 18
-2
160.9
EBITDA Growth (3Y)(%) 33.60
ILMN's EBITDA Growth (3Y)(%) is ranked higher than
89% of the 128 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.70 vs. ILMN: 33.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ILMN' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -70.3  Med: 14.55 Max: 529.1
Current: 33.6
-70.3
529.1
EPS Growth (3Y)(%) 56.40
ILMN's EPS Growth (3Y)(%) is ranked higher than
93% of the 126 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.70 vs. ILMN: 56.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ILMN' s 10-Year EPS Growth (3Y)(%) Range
Min: -40.2  Med: 5.00 Max: 205.7
Current: 56.4
-40.2
205.7
» ILMN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

ILMN Guru Trades in Q3 2014

Joel Greenblatt 12,977 sh (New)
Jim Simons 225,918 sh (New)
Steven Cohen 27,700 sh (+2977.78%)
Paul Tudor Jones 9,768 sh (+240.59%)
RS Investment Management 15,200 sh (+46.86%)
Andreas Halvorsen 8,650,670 sh (+8.23%)
Stanley Druckenmiller 410,100 sh (unchged)
First Eagle Investment 400 sh (unchged)
PRIMECAP Management 2,244,837 sh (-0.35%)
Ron Baron 1,487,075 sh (-9.39%)
Vanguard Health Care Fund 1,932,800 sh (-10.54%)
Mario Gabelli 4,100 sh (-40.58%)
George Soros 75,102 sh (-61.51%)
» More
Q4 2014

ILMN Guru Trades in Q4 2014

Julian Robertson 103,000 sh (New)
Steven Cohen 173,500 sh (+526.35%)
Jim Simons 468,918 sh (+107.56%)
First Eagle Investment 400 sh (unchged)
Stanley Druckenmiller 410,100 sh (unchged)
Vanguard Health Care Fund 1,932,800 sh (unchged)
George Soros Sold Out
Paul Tudor Jones Sold Out
PRIMECAP Management 2,241,847 sh (-0.13%)
RS Investment Management 14,850 sh (-2.30%)
Andreas Halvorsen 8,293,405 sh (-4.13%)
Ron Baron 1,408,277 sh (-5.30%)
Joel Greenblatt 7,266 sh (-44.01%)
Mario Gabelli 1,400 sh (-65.85%)
» More
Q1 2015

ILMN Guru Trades in Q1 2015

John Burbank 16,840 sh (New)
Paul Tudor Jones 1,500 sh (New)
Ray Dalio 19,457 sh (New)
Steve Mandel 2,890,103 sh (New)
RS Investment Management 60,430 sh (+306.94%)
Joel Greenblatt 13,069 sh (+79.87%)
Andreas Halvorsen 8,506,696 sh (+2.57%)
PRIMECAP Management 2,241,987 sh (+0.01%)
Julian Robertson 103,000 sh (unchged)
Vanguard Health Care Fund 1,932,800 sh (unchged)
Stanley Druckenmiller 410,100 sh (unchged)
First Eagle Investment 400 sh (unchged)
Mario Gabelli Sold Out
Ron Baron 1,219,938 sh (-13.37%)
Jim Simons 118,318 sh (-74.77%)
Steven Cohen 20,000 sh (-88.47%)
Andreas Halvorsen 8,189,589 sh (-5.33%)
» More
Q2 2015

ILMN Guru Trades in Q2 2015

Frank Sands 2,652,228 sh (New)
Steve Mandel 5,678,537 sh (+96.48%)
John Burbank 21,873 sh (+29.89%)
Vanguard Health Care Fund 2,400,500 sh (+24.20%)
Ron Baron 1,509,065 sh (+23.70%)
Julian Robertson 119,900 sh (+16.41%)
First Eagle Investment 400 sh (unchged)
Ray Dalio Sold Out
Joel Greenblatt Sold Out
Steven Cohen Sold Out
PRIMECAP Management 2,239,397 sh (-0.12%)
RS Investment Management 58,580 sh (-3.06%)
RS Investment Management 58,580 sh (-3.06%)
Paul Tudor Jones 1,300 sh (-13.33%)
Jim Simons 95,118 sh (-19.61%)
Andreas Halvorsen 4,968,956 sh (-41.59%)
Stanley Druckenmiller 206,500 sh (-49.65%)
» More
» Details

Insider Trades

Latest Guru Trades with ILMN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Illumina Inc

Meridian Funds Comments on Illumina - Aug 31, 2015

Illumina (NASDAQ:ILMN) is the leading manufacturer of high-speed machines used to sequence, analyze and "unlock the power of the human genome". The latest flagship product, HiSeq X Ten can sequence DNA at a cost of $1,000 per genome, a five order of magnitude reduction from $100 million cost when this industry was born 15 years ago.



However, at a cost of $1,000 per gene sequence, it would cost $100 million to build a gene library from 100,000 volunteers, thereby pushing researchers to focus on only the most prevalent diseases. Looking ahead, as Illumina continues to drive down gene sequencing cost at a pace faster than Moore's Law, drug companies will continue to assemble larger and larger genomic data sets and invest in increasingly powerful computing clusters to decipher the slightest genetic variations and systematically unlock new knowledge about the human genome.





Note that the cost curve improvement accelerated dramatically in 2007 which coincided with massive value creation in the biotechnology industry. Illumina is also positively impacted the broad move to digitization. Illumina acquired NextBio and is positioning to offer cloud-based delivery of DNA sequencing as a service.





Here is a link to a Reuters story discussing the expansion of DNA sequencing and the gathering of DNA data, called “precision medicine.” http://bit.ly/Precision-Medicine.



From Meridian Growth Fund’s annual letter.



Check out latest stock trades

Baron Funds Comments on Illumina Inc. - Aug 24, 2015

Illumina, Inc. (NASDAQ:ILMN) is the leading provider of next generation DNA sequencing instruments and consumables. Shares rose on reports of better-than-expected revenue and earnings driven by strong sales of sequencing instruments. We maintain conviction because we believe Illumina holds a monopoly on DNA sequencing at a time when DNA sequencing is increasingly being used in cancer research and diagnosis and reproductive health. (Neal Kaufman)



From Baron Funds' second quarter 2015 commentary.



Check out Ron Baron latest stock trades

Baron Funds Comments on Illumina Inc. - Aug 18, 2015

Illumina, Inc. (NASDAQ:ILMN) is the leading provider of next generation DNA sequencing instruments and consumables. During the past quarter, the company reported revenues and earnings that exceeded most estimates, as a result of strong sales of its core sequencing instruments. We believe that Illumina will maintain its dominant position in the DNA sequencing market and that the demand for sequencing will continue to accelerate. We believe that Illumina’s products will play important roles in several rapidly-growing clinical areas, including the markets for cancer research and diagnosis and reproductive health.





From Baron Funds' second quarter commentary.



Check out Ron Baron latest stock trades

Baron Funds Comments on Illumina Inc. - May 29, 2014

Shares of Illumina, Inc. (NASDAQ:ILMN), the leading provider of next generation DNA sequencing instruments and consumables, rose 34% in the first quarter, driven by better than expected fourth quarter financial results, strong 2014 financial guidance, and the announcement of multiple new product introductions, including an ultra-high throughput sequencing platform that will be the first to sequence a full human genome for less than $1,000. We believe Illumina has further distanced itself from its competitors and holds an effective monopoly on DNA sequencing at a time when demand is accelerating.





From Baron Funds' first quarter 2014 commentary.



Check out Ron Baron latest stock trades

Baron Funds Comments on Illumina Inc. - May 21, 2014

Shares of Illumina, Inc. (NASDAQ:ILMN), the leading provider of next generation DNA sequencing instruments and consumables, rose in the first quarter, driven by better than expected fourth quarter financial results, strong 2014 financial guidance, and the announcement of multiple new product introductions, including an ultra-high throughput sequencing platform that will be the first to sequence a full human genome for less than $1,000. We believe Illumina has further distanced itself from its competitors and holds an effective monopoly on DNA sequencing at a time when demand is accelerating. (Neal Kaufman)





From Baron Funds' first quarter 2014 letter to shareholders.



Check out Ron Baron latest stock trades

Baron Funds Comments on Illumina Inc. - May 12, 2014

Shares of Illumina, Inc. (NASDAQ:ILMN), the leading provider of next generation DNA sequencing instruments and consumables, rose during the first quarter, driven by better than expected fourth quarter financial results, strong 2014 financial guidance, and the announcement of multiple new product introductions, including an ultra-high throughput sequencing platform that will be the first to sequence a full human genome for less than $1,000. We believe Illumina has further distanced itself from its competitors and holds an effective monopoly on DNA sequencing at a time when demand is accelerating. (Neal Kaufman)



From Baron Funds' first quarter 2014 letter to shareholders.



Check out Ron Baron latest stock trades

Baron Funds Comments on Illumina Inc. - May 02, 2014

Shares of Illumina, Inc. (NASDAQ:ILMN), the leading provider of next generation DNA sequencing instruments and consumables, rose during the quarter, driven by better-than-expected fourth quarter results, strong 2014 financial guidance, and the announcement of multiple new product introductions. The company's most exciting new product is an ultra-high throughput sequencing platform that will be the first to sequence a full human genome for less than $1,000. We believe these developments support our view that Illumina has meaningfully distanced itself from its competitors. We believe that nearly all new orders in the sequencing industry are being won by Illumina, affording the company a de facto monopoly in DNA sequencing devices. Further, Illumina retains this remarkable competitive position at a time when demand for next generation DNA sequencing is accelerating rapidly.



From Baron Funds' first quarter 2014 commentary.





Check out Ron Baron latest stock trades

Top Ranked Articles about Illumina Inc

Meridian Funds Comments on Illumina Guru stock highlight
Illumina (NASDAQ:ILMN) is the leading manufacturer of high-speed machines used to sequence, analyze and "unlock the power of the human genome". The latest flagship product, HiSeq X Ten can sequence DNA at a cost of $1,000 per genome, a five order of magnitude reduction from $100 million cost when this industry was born 15 years ago. Read more...
Baron Funds Comments on Illumina Inc.
Illumina, Inc. (NASDAQ:ILMN) is the leading provider of next generation DNA sequencing instruments and consumables. Shares rose on reports of better-than-expected revenue and earnings driven by strong sales of sequencing instruments. We maintain conviction because we believe Illumina holds a monopoly on DNA sequencing at a time when DNA sequencing is increasingly being used in cancer research and diagnosis and reproductive health. (Neal Kaufman) Read more...
Baron Funds Comments on Illumina Inc.
Illumina, Inc. (NASDAQ:ILMN) is the leading provider of next generation DNA sequencing instruments and consumables. During the past quarter, the company reported revenues and earnings that exceeded most estimates, as a result of strong sales of its core sequencing instruments. We believe that Illumina will maintain its dominant position in the DNA sequencing market and that the demand for sequencing will continue to accelerate. We believe that Illumina’s products will play important roles in several rapidly-growing clinical areas, including the markets for cancer research and diagnosis and reproductive health. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 59.73
ILMN's P/E(ttm) is ranked lower than
84% of the 113 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.00 vs. ILMN: 59.73 )
Ranked among companies with meaningful P/E(ttm) only.
ILMN' s 10-Year P/E(ttm) Range
Min: 34.32  Med: 80.11 Max: 344.72
Current: 59.73
34.32
344.72
Forward P/E 47.85
ILMN's Forward P/E is ranked lower than
85% of the 75 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 21.74 vs. ILMN: 47.85 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 61.70
ILMN's PE(NRI) is ranked lower than
86% of the 112 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 28.40 vs. ILMN: 61.70 )
Ranked among companies with meaningful PE(NRI) only.
ILMN' s 10-Year PE(NRI) Range
Min: 34.5  Med: 80.23 Max: 370.09
Current: 61.7
34.5
370.09
P/B 15.76
ILMN's P/B is ranked lower than
96% of the 178 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.91 vs. ILMN: 15.76 )
Ranked among companies with meaningful P/B only.
ILMN' s 10-Year P/B Range
Min: 2.87  Med: 6.83 Max: 23.59
Current: 15.76
2.87
23.59
P/S 14.01
ILMN's P/S is ranked lower than
92% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.67 vs. ILMN: 14.01 )
Ranked among companies with meaningful P/S only.
ILMN' s 10-Year P/S Range
Min: 3.54  Med: 8.36 Max: 17.19
Current: 14.01
3.54
17.19
PFCF 83.78
ILMN's PFCF is ranked lower than
88% of the 83 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 28.56 vs. ILMN: 83.78 )
Ranked among companies with meaningful PFCF only.
ILMN' s 10-Year PFCF Range
Min: 13.32  Med: 45.35 Max: 138.5
Current: 83.78
13.32
138.5
POCF 55.14
ILMN's POCF is ranked lower than
88% of the 114 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 19.43 vs. ILMN: 55.14 )
Ranked among companies with meaningful POCF only.
ILMN' s 10-Year POCF Range
Min: 10.31  Med: 33.48 Max: 326.15
Current: 55.14
10.31
326.15
EV-to-EBIT 41.95
ILMN's EV-to-EBIT is ranked lower than
81% of the 120 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 19.58 vs. ILMN: 41.95 )
Ranked among companies with meaningful EV-to-EBIT only.
ILMN' s 10-Year EV-to-EBIT Range
Min: -97.5  Med: 39.70 Max: 415.7
Current: 41.95
-97.5
415.7
PEG 2.84
ILMN's PEG is ranked lower than
55% of the 66 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.66 vs. ILMN: 2.84 )
Ranked among companies with meaningful PEG only.
ILMN' s 10-Year PEG Range
Min: 1.21  Med: 4.17 Max: 15.23
Current: 2.84
1.21
15.23
Shiller P/E 148.27
ILMN's Shiller P/E is ranked lower than
94% of the 80 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 30.14 vs. ILMN: 148.27 )
Ranked among companies with meaningful Shiller P/E only.
ILMN' s 10-Year Shiller P/E Range
Min: 87.03  Med: 179.32 Max: 2630.5
Current: 148.27
87.03
2630.5
Current Ratio 3.09
ILMN's Current Ratio is ranked higher than
69% of the 185 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.41 vs. ILMN: 3.09 )
Ranked among companies with meaningful Current Ratio only.
ILMN' s 10-Year Current Ratio Range
Min: 0.99  Med: 4.31 Max: 60.21
Current: 3.09
0.99
60.21
Quick Ratio 2.78
ILMN's Quick Ratio is ranked higher than
72% of the 185 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.60 vs. ILMN: 2.78 )
Ranked among companies with meaningful Quick Ratio only.
ILMN' s 10-Year Quick Ratio Range
Min: 0.87  Med: 4.02 Max: 60.21
Current: 2.78
0.87
60.21
Days Inventory 121.14
ILMN's Days Inventory is ranked higher than
53% of the 183 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 128.59 vs. ILMN: 121.14 )
Ranked among companies with meaningful Days Inventory only.
ILMN' s 10-Year Days Inventory Range
Min: 78.57  Med: 112.59 Max: 318.15
Current: 121.14
78.57
318.15
Days Sales Outstanding 64.97
ILMN's Days Sales Outstanding is ranked lower than
53% of the 161 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 63.01 vs. ILMN: 64.97 )
Ranked among companies with meaningful Days Sales Outstanding only.
ILMN' s 10-Year Days Sales Outstanding Range
Min: 56.76  Med: 80.89 Max: 185.88
Current: 64.97
56.76
185.88

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 87.05
ILMN's Price/Net Current Asset Value is ranked lower than
95% of the 112 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.89 vs. ILMN: 87.05 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ILMN' s 10-Year Price/Net Current Asset Value Range
Min: 1.95  Med: 11.19 Max: 2050.89
Current: 87.05
1.95
2050.89
Price/Tangible Book 36.59
ILMN's Price/Tangible Book is ranked lower than
95% of the 157 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.27 vs. ILMN: 36.59 )
Ranked among companies with meaningful Price/Tangible Book only.
ILMN' s 10-Year Price/Tangible Book Range
Min: 1.18  Med: 7.79 Max: 457.79
Current: 36.59
1.18
457.79
Price/Projected FCF 5.52
ILMN's Price/Projected FCF is ranked lower than
87% of the 95 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.76 vs. ILMN: 5.52 )
Ranked among companies with meaningful Price/Projected FCF only.
ILMN' s 10-Year Price/Projected FCF Range
Min: 1.53  Med: 5.28 Max: 72.48
Current: 5.52
1.53
72.48
Price/Median PS Value 1.69
ILMN's Price/Median PS Value is ranked lower than
81% of the 166 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.15 vs. ILMN: 1.69 )
Ranked among companies with meaningful Price/Median PS Value only.
ILMN' s 10-Year Price/Median PS Value Range
Min: 0.48  Med: 1.04 Max: 90.75
Current: 1.69
0.48
90.75
Price/Peter Lynch Fair Value 2.44
ILMN's Price/Peter Lynch Fair Value is ranked lower than
69% of the 48 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.00 vs. ILMN: 2.44 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
ILMN' s 10-Year Price/Peter Lynch Fair Value Range
Min: 1.73  Med: 2.90 Max: 9.68
Current: 2.44
1.73
9.68
Price/Graham Number 9.79
ILMN's Price/Graham Number is ranked lower than
97% of the 90 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.52 vs. ILMN: 9.79 )
Ranked among companies with meaningful Price/Graham Number only.
ILMN' s 10-Year Price/Graham Number Range
Min: 3.3  Med: 5.89 Max: 48.38
Current: 9.79
3.3
48.38
Earnings Yield (Greenblatt) (%) 2.38
ILMN's Earnings Yield (Greenblatt) (%) is ranked lower than
53% of the 184 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.90 vs. ILMN: 2.38 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ILMN' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 0.2  Med: 2.10 Max: 7.2
Current: 2.38
0.2
7.2
Forward Rate of Return (Yacktman) (%) 25.78
ILMN's Forward Rate of Return (Yacktman) (%) is ranked higher than
87% of the 92 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 12.13 vs. ILMN: 25.78 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
ILMN' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: -9.3  Med: 0.90 Max: 38.1
Current: 25.78
-9.3
38.1

Analyst Estimate

Dec15 Dec16 Dec17
Revenue(Mil) 2,250 2,665 3,078
EPS($) 3.40 4.14 5.11
EPS without NRI($) 3.40 4.14 5.11

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:ILU.Germany, ILMN.Mexico,
Illumina Inc was incorporated in California in April 1998 and reincorporated in Delaware in July 2000. The Company provides sequencing-and array-based solutions for genetic analysis. Its products enabled researchers to explore DNA, helping them create the first map of gene variations associated with health, disease, and drug response. The Company's customers includegenomic research centers, academic institutions, government laboratories, hospitals, and reference laboratories as well as pharmaceutical, biotechnology, agrigenomics, commercial molecular diagnostic, and consumer genomics companies. The Company's portfolio of integrated systems, consumables, and analysis tools is designed to accelerate and simplify genetic analysis. This portfolio addresses a range of genomic complexity, price points, and throughput, enabling customers to select the solution for their research or clinical challenge. It also provides products and services for other life sciences applied markets such as agrigenomics. Government and corporate researchers use its sequencing and array-based tools to accelerate and enhance agricultural research. In addition to selling products, the company provides genotyping, NIPT, and whole-genome sequencing services. The Company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region. In each of these areas, dedicated sales, service, and application-support personnel are expanding and supporting their respective customer bases. In addition, it sells through life-science distributors in certain markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and South Africa. The manufacturing operations require a wide variety of raw materials, electronic and mechanical components, chemical and biochemical materials, and other supplies. Multiple commercial sources provide many of its components and supplies, but there are some raw materials and components that the company obtains from single-source suppliers. The Company's competitors include Affymetrix, Inc., Agilent Technologies, Inc., BGI, Pacific Biosciences of California, Inc., QIAGEN N.V., Roche Holding AG., and Thermo Fisher Scientific, Inc., among others. The Company's operations are regulated by governmental authorities and FDA in the United State.
» More Articles for ILMN

Headlines

Articles On GuruFocus.com
Meridian Funds Comments on Illumina Aug 31 2015 
Meridian Equity Income Fund Annual Report 2015 Aug 31 2015 
Baron Funds Comments on Illumina Inc. Aug 24 2015 
Baron Funds Comments on Illumina Inc. Aug 18 2015 
shortlist Jul 19 2015 
shortlist Jul 19 2015 
shortlist Jul 19 2015 
San Diego-Based Illumina Inc's Stock Is Overvalued Jun 16 2015 
CalAmp and Illumina Significant Earnings Growth; Perrigo Rebuffs Takeover Offer Apr 22 2015 
Douglas C. Lane's Top Three Stocks for Q1 2015 Apr 14 2015 

More From Other Websites
What Illumina Gets With GenoLogics Life Science Software Sep 01 2015
Illumina Completes Acquisition of GenoLogics Sep 01 2015
Illumina Completes Acquisition of GenoLogics Sep 01 2015
Ambarella Leads 4 Top Stocks With Rising Estimates Aug 28 2015
Illumina (ILMN) Stock Initiated with a 'Buy' Rating at Cantor Fitzgerald Aug 27 2015
Coverage initiated on Illumina by Cantor Fitzgerald Aug 27 2015
Burning Rock and Illumina Collaborate on Molecular Diagnostics for Oncology Aug 24 2015
Burning Rock and Illumina Collaborate on Molecular Diagnostics for Oncology Aug 24 2015
Burning Rock and Illumina Collaborate on Molecular Diagnostics for Oncology Aug 24 2015
LabCorp Reaching Past Doctor's Office To The Patient Aug 24 2015
RainDance pulls IPO citing market conditions Aug 24 2015
Illumina Creates Helix: Here's What It Is, And What It's Worth Aug 19 2015
Illumina Launches New Consumer-Genomics Startup Aug 18 2015
Gene-sequencing tech provider Illumina secures investors to create $100 million gene-sequencing... Aug 18 2015
Illumina, Warburg Pincus Form Genetic-Testing Startup Helix Aug 18 2015
Illumina, Warburg Pincus, and Sutter Hill Ventures Form Helix to Accelerate Consumer Adoption of... Aug 18 2015
Illumina partners with private equity firm on gene JV -sources Aug 18 2015
Illumina, Warburg Pincus, and Sutter Hill Ventures Form Helix to Accelerate Consumer Adoption of... Aug 18 2015
Short Sellers Wary Of Biotech Stocks Aug 14 2015
5 Top BioPharma Stocks That May Have Sold Off Too Much and Become Bargains Aug 12 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK